On September 22nd, some investors asked 688621.SH: the company's innovation drug sector has increased a lot of business, but it still lacks a very important GLP safety review. Can it be made up as soon as possible in the future?
Yang Guangnuo and reply: dear investors, how do you do? Thank you for your suggestion to the company, the company will plan to expand the field according to its own business development plan.